• Je něco špatně v tomto záznamu ?

The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia

D. Sojakova, J. Husakova, V. Fejfarova, A. Nemcova, R. Jarosikova, S. Kopp, V. Lovasova, EB. Jude, M. Dubsky

. 2024 ; 25 (18) : . [pub] 20240923

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018871

Grantová podpora
LX22NPO5104 National Institute for Research on Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104), funded by the European Union Next-Generation EU.

Autologous cell therapy (ACT) is primarily used in diabetic patients with chronic limb-threatening ischemia (CLTI) who are not candidates for standard revascularization. According to current research, this therapy has been shown in some studies to be effective in improving ischemia parameters, decreasing the major amputation rate, and in foot ulcer healing. This review critically evaluates the efficacy of ACT in patients with no-option CLTI, discusses the use of mononuclear and mesenchymal stem cells, and compares the route of delivery of ACT. In addition to ACT, we also describe the use of new revascularization strategies, e.g., nanodiscs, microbeads, and epigenetics, that could enhance the therapeutic effect. The main aim is to summarize new findings on subcellular and molecular levels with the clinical aspects of ACT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018871
003      
CZ-PrNML
005      
20241024111123.0
007      
ta
008      
241015s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms251810184 $2 doi
035    __
$a (PubMed)39337669
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Sojakova, Dominika $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 14021 Prague, Czech Republic $1 https://orcid.org/0009000235103993
245    14
$a The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia / $c D. Sojakova, J. Husakova, V. Fejfarova, A. Nemcova, R. Jarosikova, S. Kopp, V. Lovasova, EB. Jude, M. Dubsky
520    9_
$a Autologous cell therapy (ACT) is primarily used in diabetic patients with chronic limb-threatening ischemia (CLTI) who are not candidates for standard revascularization. According to current research, this therapy has been shown in some studies to be effective in improving ischemia parameters, decreasing the major amputation rate, and in foot ulcer healing. This review critically evaluates the efficacy of ACT in patients with no-option CLTI, discusses the use of mononuclear and mesenchymal stem cells, and compares the route of delivery of ACT. In addition to ACT, we also describe the use of new revascularization strategies, e.g., nanodiscs, microbeads, and epigenetics, that could enhance the therapeutic effect. The main aim is to summarize new findings on subcellular and molecular levels with the clinical aspects of ACT.
650    _2
$a lidé $7 D006801
650    12
$a autologní transplantace $7 D014182
650    _2
$a chronická kritická ischemie končetin $x terapie $7 D000089802
650    _2
$a buněčná a tkáňová terapie $x metody $7 D064987
650    _2
$a ischemie $x terapie $7 D007511
650    _2
$a transplantace mezenchymálních kmenových buněk $x metody $7 D045164
650    _2
$a diabetes mellitus $x terapie $7 D003920
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Husakova, Jitka $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 14021 Prague, Czech Republic
700    1_
$a Fejfarova, Vladimira $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
700    1_
$a Nemcova, Andrea $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
700    1_
$a Jarosikova, Radka $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
700    1_
$a Kopp, Simon $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
700    1_
$a Lovasova, Veronika $u Transplantation Surgery Department, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u Second Faculty of Medicine, Charles University, 15006 Prague, Czech Republic $1 https://orcid.org/0000000326597725
700    1_
$a Jude, Edward B $u Diabetes Center, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne OL6 9RW, UK $u Department of Endocrinology and Gastroenterology, University of Manchester, Manchester M13 9PL, UK
700    1_
$a Dubsky, Michal $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 14021 Prague, Czech Republic $1 https://orcid.org/0000000220780177 $7 xx0105570
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 25, č. 18 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39337669 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111117 $b ABA008
999    __
$a ok $b bmc $g 2201625 $s 1230844
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 25 $c 18 $e 20240923 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a LX22NPO5104 $p National Institute for Research on Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104), funded by the European Union Next-Generation EU.
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace